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Abstract
Introduction The National Lipid Association Statin Intol-
erance (SI) Panel recognized the need for better under-
standing of the patient SI experience.
Objective The objective of this research was to develop a
patient-reported outcome (PRO) questionnaire to assess a
patient’s experience with SI.
Methods Questionnaire development was informed via a
series of research activities: literature review, concept
elicitation, item generation, and content evaluation. Fol-
lowing the literature review and concept elicitation, a draft
questionnaire was constructed and subsequently modified
based on feedback from therapeutic area experts and
patients via cognitive debriefing interviews.
Results Muscle-related symptoms were the most com-
monly reported symptoms associated with SI in the
literature review (35 of 41 articles reviewed [85%]) and in
semi-structured interviews with experts (n = 5 [100%])
and patients (n = 17 of 20 [85.0%]). Physical and other
impacts of SI symptoms on daily activities were also fre-
quently reported. A 17-item draft questionnaire was cre-
ated, and cognitive debriefing with experts (n = 5) and
patients (n = 15) was conducted. Overall, the items,
response options, and instructions were comprehensible
and positively reviewed; minor changes resulted in the
15-item Statin Experience Assessment Questionnaire
(SEAQ). Using a 30-day recall period, the SEAQ
assesses the severity and impact of six SI symptoms
(muscle ache, muscle pain, muscle cramps, muscle weak-
ness, tiredness, and joint pain) on an 11-point numeric
scale. Statin discontinuation and likelihood of discontinu-
ation due to symptoms are assessed and scored on a yes/no
and five-point verbal response scale, respectively.
Conclusion The SEAQ is a novel content-valid PRO
questionnaire that assesses patient SI experience and fos-
ters dialogue about SI between patients and providers.
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Key Points for Decision Makers
Statins are widely prescribed and generally well
tolerated for the treatment of hypercholesterolemia.
However, statin intolerance has an estimated
prevalence of up to 25% in the population.
The National Lipid Association Statin Intolerance
Panel has emphasized statin intolerance as best
understood from a patient-centric perspective.
Furthermore, better communication between patients
and providers regarding statin intolerance is needed.
No validated tools that assess the patient experience
with statin use currently exist.
This article describes the development of the
content-valid Statin Experience Assessment
Questionnaire with the goal of identifying statin
intolerance in clinical settings and fostering
communication about statin intolerance between
patients and providers. The use of this questionnaire
will allow shared learning between patients and
providers in identifying and evaluating statin
intolerance.
1 Introduction
Hypercholesterolemia is a major risk factor for cardiovas-
cular disease (CVD), which accounts for nearly one in
three deaths in the USA [1]. The estimated annual costs
associated with CVD in the USA are more than $US320
billion (approximately $US196 billion in direct costs and
$US124 billion in indirect costs). Statins, or 3-hydroxy-3-
methylglutaryl-coenzyme A reductase inhibitors, are rec-
ommended by current cholesterol management guidelines
as the initial drug treatment of choice for individuals with
elevated cholesterol levels and/or cardiovascular risk for
whom lifestyle change alone is insufficient [2–6].
Despite the general tolerability and widespread use of
statins, they can be associated with untoward side effects,
including muscle symptoms, gastrointestinal symptoms,
headache, and liver abnormalities [7, 8]. Statin intolerance
(SI) can be associated with some of these side effects. It is
estimated from randomized controlled trials, patient sur-
veys, and retrospective studies that muscle-related symp-
toms occur in 5–25% of patients being treated with statins
[9–15]. Furthermore, primarily as a result of muscle-related
symptoms, SI is a major cause of nonadherence, dose
reduction, and discontinuation of statins [16–18] and may
contribute to the high cost of CVD and affect clinical
outcomes [19]. Thus, there is a need for a better under-
standing of the patient with SI [20].
In 2014, the National Lipid Association (NLA) SI Panel
recognized this need for a better understanding of the SI
experience, best defined in the context of a patient-centric
perspective, as well as the need for appropriately developed
SI scales that can assess the phenomenon and bothersome
impacts of SI directly from the perspective of the patient
[17]. The viewpoint is consistent with the American Col-
lege of Cardiology (ACC)/American Heart Association
(AHA) Task Force on Performance Measures, which
emphasized the importance of ‘‘shared accountability’’
among patients and providers and the impact this could
have on treatment decisions and ultimately clinical out-
comes [21]. Therefore, tools are needed to assess SI from
the patient perspective, but—according to current litera-
ture—no such suitable measures exist. The objective of the
current research activities was to develop a patient-reported
outcome (PRO) questionnaire for use in real-world settings
to evaluate patient-centric attributes of SI. The tool is
intended to help foster communication between patients
and providers and to construct a means by which the
complaints about and patient burden of SI may be quanti-
fied. In addition, the questionnaire should aid in a better
understanding and documentation of the experiences of
patients with SI and allow the systematic collection of
patient-centric data in research settings.
2 Methods
To identify and describe the symptoms and impacts that
characterize SI, an empirical literature review of SI, advice
meetings with SI experts, and interviews with patients who
are statin intolerant were conducted. Results from these
activities informed the selection of concepts for measure-
ment and the construction of the PRO questionnaire. The
questionnaire content was then assessed among clinical
experts and patients with SI (Fig. 1).
2.1 Literature Review
Peer-reviewed literature regarding SI was limited to
English-language studies published between 2006 and 4
November 2014. The search was conducted in MED-
LINE, Embase, and PsycINFO using the OvidSP plat-
form. Search queries included statin intolerance and
these related terms: statin-intolerance, statin-induced, and
statin therapy. Additionally, terms for signs, symptoms,
side effects, impacts, and adverse events were used to
narrow search results. The search was supplemented with
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articles identified by the members of the research team
or manual review of reference lists that were not cap-
tured in the initial search. Relevant articles with a pri-
mary focus on signs, symptoms, side effects, adverse
events, and/or impacts of statins and/or SI were identi-
fied and retrieved. Articles were excluded if they (1)
primarily focused on the pathogenesis, genetics, or
molecular biology of SI without discussion of signs,
symptoms, side effects, adverse events, and/or impacts of
statins and/or SI; (2) solely discussed statins used in
combination with other non-statin drugs; or (3) solely
discussed case studies of three or fewer patients. Key
concepts associated with SI were extracted and informed
the development of an SI conceptual model as well as
documentation describing those concepts and justifying
their relevance to the condition. The ‘Warnings and
Precautions’ and ‘Adverse Reactions’ sections of the
product labels for three commonly used drugs for the
treatment of hypercholesterolemia, that is, atorvastatin
(Lipitor), ezetimibe/simvastatin (Vytorin), and ezetimibe
(Zetia), were reviewed for side effects. The targeted
literature review was conducted early in the research
process to document any untoward effects of lipid-
modifying therapies assumed to be effective. All poten-
tially effective lipid-modifying therapies were included
in an effort to understand and document any similarities
among or differences between therapies.
2.2 Concept Elicitation
2.2.1 Patient Interviews
Patients were recruited by providers who were specialists
in internal medicine (n = 3), cardiology (n = 2), or pri-
mary care (n = 2). Individual concept-elicitation inter-
views (CEIs) were conducted using a semi-structured
interview guide to explore the concepts relevant and
important to the patients who experienced SI. The guide
served as a map rather than a verbatim script to be refer-
enced during the interviews to capture complete and
meaningful information related to the research questions
while maintaining spontaneity. Patients were asked a series
of open-ended questions about their experience with statins
and associated impacts on quality of life. Open-ended
follow-up questions were used to clarify concepts (e.g.,
concept severity, frequency, and duration) and to encour-
age elicitation of all pertinent concepts associated with SI.
This method of inquiry avoids the use of leading questions
that may bias patients’ responses and allows the experience
to be described in the patient’s own language. Interviewers
were trained in good interviewing practices, National
Institutes of Health Participant Protection, sponsor adverse
event reporting, and internal data protection. Mock inter-
views were conducted with the interviewers to ensure good
interviewing practices and to identify any issues. The final
Fig. 1 Overall methodology schematic. SEAQ Statin Experience Assessment Questionnaire, SI statin intolerance
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sample size was justified by achievement of saturation (i.e.,
the stage in the data assembly process when no new rele-
vant information is obtained) [22–25]. Patients aged
C18 years, having primary hypercholesterolemia
(heterozygous familial hypercholesterolemia [FH] or non-
FH) with moderate, high, or very high cardiovascular risk,
and having the inability to tolerate one or more statin (i.e.,
modified statin dose level or frequency, recommended new
statin, or discontinued statin) because of objectionable
symptoms (real or perceived) within the 3 months prior to
screening were included in the study. FH diagnosis and
cardiovascular risk level were identified by the provider via
a yes/no response and check box option, respectively.
Patients with a diagnosis of fibromyalgia or a history of the
following conditions were excluded from the study: severe
neuropathic pain; rheumatological disease associated with
symptoms that may be confounded by symptoms of SI
(e.g., rheumatoid arthritis); myalgia or myopathy that
began or increased during treatment with lipid-modifying
therapy other than statin therapy and stopped when the
lipid-modifying therapy was discontinued; myopathy, other
than statin-associated myopathy; rhabdomyolysis (defined
as evidence of organ damage with creatine kinase
[10,000 IU/l); or homozygous FH. Interviews lasted
approximately 1 h and were audio-recorded, transcribed
verbatim by an independent transcription company, and
analyzed as described subsequently. Before the study was
conducted, all study documents were submitted to an ethics
review board for consideration, and approval to execute the
interviews was received from Copernicus Group Indepen-
dent Review Board (CGIRB) on 3 February 2015.
2.2.2 Expert Advice Meetings
Individual expert advice meetings were conducted with
physicians and nurse practitioners who were experienced
with treating patients with SI and who were identified
from peer-reviewed publications in cardiovascular and SI
research. A semi-structured open-ended expert advice
meeting guide was developed to reference during the
interviews conducted between 1 December 2014 and 5
January 2015. As with the patient interviews, interviews
were conducted by trained interviewers, and the guide
served as a map rather than a verbatim script to
encourage the spontaneous collection of relevant and
complete information related to the research questions.
Each expert was asked to define SI in his or her own
words and given the opportunity to spontaneously
describe the concepts that characterize SI. Each meeting
lasted approximately 1 h and was audio-recorded, tran-
scribed verbatim by an independent transcription com-
pany, and analyzed.
2.3 Concept Selection and Questionnaire
Construction
The goals of the concept selection and questionnaire con-
struction were to evaluate and select the primary SI-asso-
ciated concepts for measurement based on the results from
the literature review and concept-elicitation activities and
to subsequently construct the first draft of the Statin
Experience Assessment Questionnaire (SEAQ), includ-
ing specification of the mode of administration and recall
period and development of the questionnaire instructions,
items, and response options. The SEAQ draft was initi-
ated during a concept-selection and item-generation
meeting of the questionnaire developers and subsequently
finalized upon consensus. Informed by the harmonized
results of the literature search, expert advice meetings, and
patient interviews, concepts that best characterized the
relevant symptom and impacts of SI were selected as
measurement targets for the SEAQ. The SEAQ was
developed after concept selection with the following
aspects defined based on relevant information gathered
from the concept-elicitation activities, as well as mea-
surement-development best practices: purpose of assess-
ment, mode of administration, recall period, instructions,
items, and response options.
2.4 Content Evaluation
The purpose of the content evaluation was to assess the
content of the SEAQ among clinical experts and patients
with SI in ways that were acceptable to patients and could
generate results that were useful to both patients and pro-
viders. To achieve this goal, one-on-one meetings with
experts (n = 5) were conducted to evaluate the relevance,
comprehensiveness, and suitability of the SEAQ and to
modify the questionnaire, as necessary, based on these
results. Next, cognitive debriefing interviews (CDIs) with
15 patients with SI were conducted to evaluate the SEAQ
with respect to their ability to read, understand, and com-
plete the questionnaire (note that these were different
patients from those who participated in the patient CEIs).
Results from each of these activities informed subsequent
modifications to the SEAQ, ultimately leading to the final
tool.
During the expert advice meetings (conducted between
17 April 2015 and 1 May 2015), experts were provided the
draft SEAQ and asked open-ended questions to explore
the main research questions using a semi-structured expert
advice meeting guide. Verbatim interview transcriptions
were coded and analyzed. Interim modifications to the
SEAQ based on expert feedback were made before the
debriefing interviews with patients.
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Individual patient CDIs were conducted following
interim modifications using a semi-structured cognitive
debriefing interview guide. Patients were included in this
phase of the study if they met the inclusion criteria
described previously for the concept-elicitation phase of
the study. Interviews were audio-recorded, transcribed
verbatim, and analyzed. After feedback from expert advice
meetings and patient CDIs was received, the SEAQ was
modified to generate the final version. Before interviews,
all study documents were submitted to an ethics review
board for consideration. Approval to conduct the inter-
views was received from CGIRB on 8 April 2015.
2.5 Qualitative Data Analyses
Verbatim transcripts were entered into ATLAS.ti Version
7.5.2 to facilitate the organization and analysis of qual-
itative data [26]. Transcript text germane to the research
questions was identified, highlighted, and matched to a
code from a codebook that best characterized the data.
The codebook, a comprehensive list of all of the codes
used to characterize important segments of transcript
text, was used as a guide to organize the content and
meaning of actual subject language. Several researchers
or coders performed the coding by identifying transcript
text in which a subject expressed an SI-related experi-
ence (i.e., a concept). When the data could not be
matched to an existing code, a new code was created.
The semi-structured CEI guide served as the basis for
the preliminary coding scheme, which was updated as
the coders analyzed the transcripts and added or modi-
fied codes. Codes added or modified were shared with all
coders to maintain consistency with the scheme. A senior
member of the project team reviewed the coding of
every transcript to minimize variability across coders and
to ensure inter-coder reliability. After completion of
coding, data were pooled and qualitatively analyzed for
common themes.
To facilitate coding in the concept-elicitation phase, the
composition of each individual code followed this basic
structure: domain::root concept::descriptor. ‘Domain’
conveyed the overarching general concept into which a
specific root concept fell (e.g., symptom or impact). ‘Root
concept’ was the unique characteristic of SI described by
the expert or patient that was unlike any other concept
(e.g., muscle pain). The ‘descriptor’ was intended to
characterize, clarify, or otherwise describe some aspect of
the root concept (e.g., a descriptor code may offer detail
such as severity, frequency, duration, or location). Concept
frequency was determined by counting the number of
unique experts or patients who mentioned the concept at
least once during an interview.
For the content-evaluation phase, a codebook organized
feedback on the questionnaire. Coding was performed as
described previously for the CEIs. The preliminary coding
scheme was based on the semi-structured expert advice
meeting guide or patient interview guide and was updated
as transcripts were analyzed. Responses were compared
and aggregated around themes associated with particular
segments of the questionnaire (i.e., instructions, items,
response options, and recall period) and more general
topics such as the utility of the measure and overall format.
A semi-quantitative analysis entailed counting the number
of unique expert responses captured under a theme. Con-
tent analysis of patient responses consisted of evaluating
patient interpretation of the instructions, items, and
response options against their intended meaning.
3 Results
3.1 Literature Review
The literature review included 41 articles (19 review arti-
cles and 22 primary research articles) [9, 11, 15, 17, 27–63]
(Fig. 2) and labels from three commonly prescribed lipid-
modifying drugs [64–66]. Of the 41 articles reviewed, only
four provided a working definition of SI [17, 51, 52, 63].
The literature described SI broadly as being any symptom
significant enough to warrant a change in treatment. All
three drug labels and 35 of the 41 articles reviewed
reported muscle-related symptoms. SI concepts reported in
the literature and labels included myalgia, myositis,
myopathy, rhabdomyolysis, muscle atrophy, diminished
muscle coordination, tendon pain/tendonitis, alopecia,
renal impairment, liver enzyme abnormality, sleep distur-
bances, indigestion, headache, blisters, and nausea (Table 1
in the Electronic Supplementary Material [ESM]). The
concepts identified in the literature review were organized
into two conceptual models: one depicting SI (Fig. 1a in
the ESM) and one depicting the side effects and adverse
events associated with statins, as concepts specifically in
the context of SI were often difficult to discern (Fig. 1b in
the ESM). Conceptual models illustrate the relationship
between a specified condition and its proximal to distal
health outcomes [67]. These outcomes can be either uni-
dimensional and have a direct relationship to the condition
or multidimensional and indirectly relate to the condition.
These models are not intended to be causal; arrows imply a
dominant causal pathway, but a lack of arrows does not
imply the absence of a relationship. The ultimate goal of
this research was to generate a harmonized conceptual
model incorporating the literature review and concept-
elicitation activities.
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3.2 Concept Elicitation
Five experts (four physicians and one nurse practitioner)
from diverse geographical areas in the USA and with a
reported patient treatment experience of 19–29 years
agreed to participate (Table 2 in the ESM). Each expert
provided a unique definition of SI, and four (80.0%)
reported that SI is different from experiencing side effects
with statins. A total of 13 concepts reflecting the patient
experience with SI were identified: muscle pain (n = 5
[100.0%]), muscle weakness (n = 4 [80.0%]), and forget-
fulness (n = 2 [40.0%]), with burping, constipation, diar-
rhea, fatigue, gas, headache, indigestion, muscle cramps,
reflux, and upset stomach being reported by one expert
each. Experts frequently reported impacts on physical
activity and daily living (e.g., inability to get out of bed or
chair [n = 3 (60.0%)], difficulty walking [n = 3 (60%)],
and impact on general daily activities [n = 3 (60.0%)]).
The concepts generated from these meetings were orga-
nized into a conceptual model (Fig. 2 in the ESM).
Table 1 describes the characteristics of the 20 patients
who participated in CEIs, including demographics, general
health, and statin therapeutic history. Patients were nearly
evenly divided on whether they were familiar with the term
‘statin intolerance’ (55.0% familiar vs. 45.0% unfamiliar).
The majority of patients who were familiar with the term
(n = 7 [63.6%]) reported that SI was related to experi-
encing side effects. The saturation analysis of SI-related
symptom data concluded that saturation was achieved (i.e.,
no new symptoms were elicited during the final quartile of
interviews; Table 3 in the ESM). Patients reported 37
impact-level SI concepts across the following ten domains:
emotional (n = 15 [75.0%]), activities of daily living
(n = 13 [65.0%]), physical (n = 11 [55.0%]), social
(n = 7 [35.0%]), sleep (n = 6 [30.0%]), work (n = 3
[15.0%]), cognitive (n = 2 [10.0%]), leisure (n = 2
[10.0%]), attire (n = 1 [5.0%]), and identity (n = 1
[5.0%]). Generated concepts were organized in a concep-
tual model (Fig. 3 in the ESM).
3.3 SEAQ Development
Harmonized concepts from the literature review and the
concept elicitations (Table 2) were utilized to generate a
17-item draft questionnaire (Fig. 4 in the ESM). One set of
items assesses the level of severity for each symptom, and the
second set assesses each symptom’s interference in daily life.
To assess severity and interference, 11-point numeric rating
scales (NRSs) were selected. The Symptom Severity Scale
uses an NRS ranging from 0 (none) to 10 (as bad as you can
imagine), and the Symptom Interference Scale ranges from 0
(not at all) to 10 (extremely). A recall period of ‘the past
30 days’ was deemed clinically appropriate to capture the
patients’ experiences between visits with their providers,
which typically occur about 1 month after initiating statin
treatment and gradually decrease over time.
Citations identified in OvidSP search for 
studies published from 2006 through 
November 4, 2014 
(n=295)
Articles retrieved for initial full-text review 
(n=15)




Abstract failing to meet criteria a
(n=265)
Additional articles retrieved for full-text reviewb
(n=15)
Articles identified from bibliographies
(n=4)
Articles failing to meet criteria a
(n=5)
Total articles included in analysis
(n=41)
Fig. 2 Literature search flow
diagram. aArticles were
included if they focused on the
signs, symptoms, side effects,
adverse events, and/or impacts
of statins, and/or statin
intolerance and excluded if they
focused on pathogenesis,
genetics, or molecular biology
of statin intolerance, or solely
discussed statins used in
combination with other drugs, in
a non-adult population (i.e.,
aged\18 years), and/or in case
studies. bFollowing review of
statin intolerance–related
articles, an additional 15 articles
that primarily focused on the
side effects or adverse events of
statins were selected from the
initial list of 295 abstracts for
full-text review
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3.4 Content Evaluation
The initial 17-item draft SEAQ was debriefed with the
same experts who participated in the concept elicitation.
Expert feedback received after review of the draft SEAQ
confirmed the relevance of the muscle-related items in the
questionnaire (n = 5 [100.0%]); however, two experts
(40.0%) disagreed on the relevance of non–muscle-related
items. All experts agreed on the severity and interference
assessment of symptoms, and all but one expert (80.0%)
indicated that the 30-day recall period was appropriate.
Experts also made suggestions regarding the instructions,
NRS, overall format, and additional information to be
collected from the questionnaire. As a result of the feed-
back, two additional items were added to the SEAQ
during an interim modification before conducting CDIs
with patients: one item asking patients whether they stop-
ped taking their statin because of symptoms (using a
dichotomous yes/no response scale) and another item
asking patients how likely they would be to stop taking
their statin because of symptoms (rated on a five-point
verbal response scale).
The patients who participated in the CDIs were unique
from those who participated in the CEIs, but their char-
acteristics were similar (Table 1). A summary of results
from the patient CDIs is included in Table 4 in the ESM.
All patients (n = 15) reported that the SEAQ was easy to
read and answer. All patients for whom data were collected
(n C 13 [100.0%]) interpreted the instructions and
response scales as intended; data were not available for
patients who were not asked a specific question and/or who
provided a response that was not sufficient for analysis. At
Table 1 Provider- and patient-
reported demographic and
health information of patients
who participated in concept-
elicitation interviews and
cognitive debriefing interviews
Characteristic CEIs (N = 20) CDIs (N = 15)
Age, years
Range 55.9–78.9 48.2–74.2
Mean ± SD 65.6 ± 7.4 62.9 ± 9.1
Sex, female 13 (65.0) 9 (60.0)
CV risk
Moderate 7 (35.0) 5 (33.3)
High 8 (40.0) 5 (33.3)
Very high 5 (25.0) 5 (33.3)
Currently taking a statin 17 (85.0) 13 (86.7)
No lactose intolerance 20 (100.0) 14 (93.3)
No vitamin D deficiency 19 (95.0) 13 (86.7)
Hypothyroidism
Yes (currently controlled) 3 (15.0) 1 (6.7)
No 17 (85.0) 14 (93.3)
Health in general
Excellent 0 (0.0) NR
Very good 2 (10.0) 1 (6.7)
Good 10 (50.0) 7 (46.7)
Fair 6 (30.0) 5 (33.3)
Poor 2 (10.0) 2 (13.3)
Patient-reported statin medication historya
Type(s) of statin medication had been changed 11 (55.0) NR
Statin medication had been discontinued 5 (25.0) NR
Dosage(s) of statin medication had been changed 4 (20.0) NR
Statin medication dose/type had not been changed 2 (10.0) NR
Medications other than statinsa
Antihypertensive medications 6 (30.0) 12 (80.0)
Diabetes medications 2 (10.0) 3 (20.0)
Data are presented as n (%) unless otherwise indicated
CDI cognitive debriefing interview, CEI concept-elicitation interview, CV cardiovascular, NR not reported,
SD standard deviation
a Counts not mutually exclusive
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least 93% of patients for whom data were collected inter-
preted each item as intended. The majority of patients
found the muscle-related items (as well as joint pain and
tiredness items) relevant to their experience with SI
(ranging from n = 10 [66.7%] to n = 15 [100.0%]
patients), whereas headache and nausea were experienced
by less than half of the patients for whom data were col-
lected (n = 6 [40.0%] and n = 2 [13.3%], respectively).
The removal of nausea and headache from the SEAQ as
target measurement concepts was the only change based
directly on patient feedback. All experts (n = 5 [100.0%])
and patients (n = 15 [100.0%]) indicated that the SEAQ
would aid in facilitating patient–provider communication.
Based on expert feedback and CDIs with patients, the
following modifications were made to the SEAQ
instructional text: indication that some people have no
negative or unwanted symptoms (60.0% of experts agreed);
adjustment to the NRS to include a middle anchor to rep-
resent the severity/interference of moderate symptoms
(80.0% of experts agreed); reordering of muscle-related
symptoms from least invasive (based on one expert rec-
ommendation); and removal of nausea and headache from
the questionnaire as target concepts based on irrelevance to
SI according to some experts (n = 2 [40.0%]) and the
majority of patients (headaches and nausea were not rele-
vant to 7 [53.8%] and 12 [80.0%] patients, respectively).
Figure 3 presents the final 15-item SEAQ. After final-
ization of the SEAQ, a conceptual framework was con-
structed to depict the relationship between the concepts and
subsequent items in the instrument (Fig. 4) [68].
Scoring of the SEAQ is based on the conceptual
framework, which hypothesized a symptom severity scale
(items 1–6), a symptom interference scale (items 7–12),
and three additional items assessing ‘overall impact’
(item 13), whether the respondent stopped taking statins as
prescribed (item 14), and intention to stop taking statins
(item 15). A symptom severity scale score is created by
summing and averaging responses to items 1 through 6,
and a symptom interference scale score by summing and
averaging responses from items 7 through 12. Addition-
ally, a combined total score can be created by averaging the
scores of all items from both the symptom severity and the
symptom interference scales (items 1–12). Finally, the
items assessing overall impact (item 13) and whether the
respondent stopped taking statins as prescribed (item 14) or
intends to stop taking statins (item 15) are scored inde-
pendently. For the dichotomously scored item 14, we rec-
ommend a 0 (no) and 1 (yes) scoring method. Item 15 may
be scored from 0 (very likely) to 4 (very unlikely).
4 Discussion
The primary purpose of the development of the content-
valid SEAQ is to facilitate clinically meaningful com-
munication between patients and their providers to improve
the understanding of SI and its associated patient experi-
ence. To date, no validated scales accurately assess the
patient SI experience in the clinic. Although new and
proposed tools for providers are becoming available, they
do not allow for direct input from the patient, an important
component of SI diagnosis and management. The statin
myalgia clinical index (SMCI) score proposed by the NLA
provides weighted values based on the distribution of
muscle complaints, information on the temporal pattern of
onset and improvement after withdrawal from statins, and
reoccurrence on rechallenge [69]. Additionally, the ACC
has implemented an SI app to help guide providers through


































a Described as joint pain by patients and in the literature. Expert-reported ‘muscle pain’ around the joints
b Described similarly by patients as muscle cramps; however, patients who reported this symptom indicated the two were distinct based on
duration
c Patient-reported ‘body ache’. Expert-reported ‘muscle ache’ sometimes described by patients as ‘body ache’
d Patient-reported ‘runny nose’. Sinusitis reported as a side effect or adverse event in the product label for ezetimibe
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Stan Experience Assessment Quesonnaire (SEAQ) (© 2015)
A stan is a medicaon used to lower cholesterol and somemes people will have negave or unwanted 
experiences because of these medicaons and some people do not. This quesonnaire asks about your 
experiences with taking stans. Please select only one answer for each queson by circling the number that 




Moderate    

As bad as you 
can imagine

1. Rate the severity of your muscle aches (for 
example, muscles feeling sore, strained or 
sﬀ).  
0 1 2 3 4 5 6 7 8 9 10
2. Rate the severity of your muscle pain (for 
example, a throbbing or shoong pain in 
the muscles).  
0 1 2 3 4 5 6 7 8 9 10
3. Rate the severity of your muscle cramps. 0 1 2 3 4 5 6 7 8 9 10
4. Rate the severity of your muscle 
weakness (for example, a feeling of 
heaviness or redness in the muscles).
0 1 2 3 4 5 6 7 8 9 10
5. Rate the severity of your redness (or 
lack of energy). 0 1 2 3 4 5 6 7 8 9 10
6. Rate the severity of your joint pain. 0 1 2 3 4 5 6 7 8 9 10
7. How much has muscle aches (for 
example, muscles feeling sore, strained or 
sﬀ) interfered with your daily life?  
0 1 2 3 4 5 6 7 8 9 10
8. How much has muscle pain (for example, 
a throbbing or shoong pain in the 
muscles) interfered with your daily life?  
0 1 2 3 4 5 6 7 8 9 10
None

Moderate    

As bad as you 
can imagine

9. How much has muscle cramps interfered 
with your daily life? 0 1 2 3 4 5 6 7 8 9 10
10. How much has muscle weakness (for 
example, a feeling of heaviness or 
redness in the muscles) interfered with 
your daily life?
0 1 2 3 4 5 6 7 8 9 10
11. How much has redness (or lack of 
energy) interfered with your daily life? 0 1 2 3 4 5 6 7 8 9 10
12. How much has joint pain interfered with 
your daily life? 0 1 2 3 4 5 6 7 8 9 10
13. Overall, how much have your stan 
medicaon symptoms interfered with 
your daily life?
0 1 2 3 4 5 6 7 8 9 10
14. Have you stopped taking your stan as 
prescribed because of your medicaon 
symptoms?
Yes No
15. Overall, how likely are you to stop taking 
your stan medicaon because of the 
symptom(s) you experience? Very 
likely
Likely Unsure Unlikely Very 
unlikely
Copyright © 2015, Regeneron Pharmaceuticals, Inc.; Sanofi Biotechnology SAS No. 1-986-933.
Fig. 3 Final 15-item Statin
Experience Assessment
Questionnaire
Statin Intolerance Questionnaire Development
the process of identification, management, and treatment of
patients reporting muscle-related symptoms while taking
statins [70]. There is the potential to combine the SEAQ
with specific symptom evaluation tools such as the SMCI
as a way to use both clinical and patient-centric approaches
to assess the SI experience.
The SEAQ was developed following best practices
established by the US FDA and International Society for
Pharmacoeconomics and Outcomes Research (ISPOR)
PRO Good Research Practices Task Force [24, 68]. Best
practice guidance from the FDA for developing PRO
measures designates that content validity be supported by
evidence from qualitative studies demonstrating that the
items in a questionnaire are appropriate and comprehensive
relative to the intended measurement concept, population,
and application [68]. Patient input to item generation and
evaluation of comprehension of the questionnaire also
contribute to content validity. Patients with SI provided
input that was an integral part of the SEAQ development.
Evidence from the patient CDIs indicates that the SEAQ
was easy to complete, comprehensive, and interpreted as
intended. All patients who participated confirmed that the
resulting SEAQ would aid in the dialogue with their
providers. The concept-elicitation activities for the
SEAQ development demonstrated saturation, which
indicates that these results are robust and reliable. Research
establishes that qualitative data should be gathered to the
point of saturation to ensure that the items in a PRO
questionnaire represent the ‘universe of content’ for a
given concept [24, 25, 71–74]. According to the ISPOR
PRO Task Force, saturation should be documented when
developing a new instrument [24].
The resulting SEAQ emphasizes that the patient SI
experience is multifaceted and primarily characterized in
the context of muscle pain and weakness. Removal of
headache and nausea from the draft SEAQ aligned with
the proposed SI definitions from the NLA, International
Lipid Expert Panel, and European Atherosclerosis Society,
which primarily focus on muscle-related symptoms and
recognize these symptoms as the main reason for discon-
tinuation of therapy [17, 18, 75]. The SEAQ also
underscores that SI is best assessed from the patient per-
spective. This is consistent with the recommendations of
the NLA SI Panel, which highlights the importance of
collaboration between patients and providers through
effective communication for the management of SI.
According to the ACC/AHA Task Force on Performance
Measures, active engagement of patients in self-care,
Fig. 4 Statin Experience Assessment Questionnaire conceptual
framework. The left column (‘Item’) lists the specific items from
the SEAQ, the middle column (‘Concept’) lists the specific concept
of measurement as related to the item, and the right column (‘General
Concept’) is the targeted measurement domain. SEAQ Statin Expe-
rience Assessment Questionnaire
T. A. Jacobson et al.
defined by their ability to perform activities necessary to
attain, preserve, and encourage best health, leads to greater
success in achieving treatment goals. For optimal shared
accountability with their providers, patients would ideally
be aware of symptoms, discuss any symptoms with their
providers, become educated about the condition, execute a
treatment plan, and follow up to assess outcomes.
The methodology utilized for the development of the
SEAQ had several strengths. First, by obtaining data via
research interviews that allowed spontaneous responses,
experts’ definitions and characterizations of SI were not
limited to prespecified concepts about the topics. Second,
the nature of the qualitative research allowed for collection
of more in-depth data and deeper understanding of the
experts’ perspectives of SI. The experts who were inter-
viewed provided detailed input and are likely to partner
with patients to utilize the final SEAQ for a better
understanding of the patient-centric SI experience. Third,
items in the questionnaire were rated on an 11-point NRS,
suggested by researchers and measurement development
specialists because of its relative advantages in minimiza-
tion of missing data, patient preference, and ease of
recording and implementation in research settings [76].
Finally, the research activities followed the guidelines
provided by the FDA and ISPOR for the development of
PRO questionnaires.
There were also limitations in the activities leading to
the generation of the SEAQ. First, because of the small
sample size of experts and patients, additional research
would be necessary to gain further consensus on clinical
perspectives related to SI and to ensure that results are
generalizable. Second, the recall period was set to 30 days
because the questionnaire was intended to document
patient experiences between visits with their providers.
This would preclude the assessment of SI among patients
who are no longer taking statins but who had experienced
symptoms characteristic of SI in the past (i.e., longer than
30 days prior to assessment). In an effort to minimize the
burden on study participants, limited demographic and
health information was collected. In particular, detailed
information regarding the history of statin use and associ-
ated statin-related problems was lacking. The limited
demographic information collected could impair the utility
of the SEAQ in the general population. Specifically, the
lack of information regarding education and reading levels
of those patients who participated in the CDIs makes it
difficult to determine whether a broader group of patients
might find the questionnaire comprehensible and easy to
read. The last limitation is the lack of a patient review of
the final SEAQ. However, changes made to the ques-
tionnaire following patient CDIs were minor. In other
words, the most substantial changes to the SEAQ were
made after the expert advice meetings and, therefore, were
evaluated by patients. Thus, we are confident that the
current version of the SEAQ will be easily compre-
hended by future patients completing the questionnaire.
As a measure of SI, the SEAQ is a content-valid PRO
questionnaire that has been developed and documented in
accordance with measurement-development best practices.
The SEAQ can be utilized in clinical practice for shared
learning of the patient SI experience, for facilitating com-
munication between patients and providers about patient
health status, and potentially for informing treatment
decisions regarding the use of statins. In a research setting,
the SEAQ can be used as a means to gather patient-
centric data. Future research is needed to quantitatively
evaluate the psychometric properties and interpretability of
the scores and to assess the impact of the SEAQ on
treatment decision making.
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